Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/25820

Title:	Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.
Authors:	Cortés, Javier Rugo, Hope S Twelves, Chris Awada, Ahmad Perez, Edith A Im, Seock-Ah Zhao, Carol Hoch, Ute Tomkinson, Denise Buchanan, James Tagliaferri, Mary Hannah, Alison O'Shaughnessy, Joyce View more
Keywords:	Chemotherapy safety Chemotherapy side effects Etirinotecan pegol Metastatic breast cancer View more
Issue Date:	2016
Citation:	Springerplus.2016;(5)1:1033
Abstract:	New treatments with novel mechanisms of action and non-overlapping toxicities are needed for patients with metastatic breast cancer. Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor with a unique toxicity profile. The randomized phase 3 BEACON study that compared EP to treatment of physician's choice (TPC) demonstrated its clinical activity. We now present detailed safety data from the BEACON trial.
PMID:	27441152
URI:	https://hdl.handle.net/20.500.12530/25820
Rights:	openAccess
ISSN:	2193-1801
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC4938835.pdf		857.62 kB	Adobe PDF	View/Open